Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, are poor-
prognosis and low-incidence cancers, although the incidence of intrahepatic …

Hepatocellular carcinoma (HCC) is a significant cause of cancer-related morbidity and
mortality worldwide. Despite improvements in local therapies, including surgical resection …

Immune checkpoint blockade has recently emerged as a promising therapeutic approach for
various malignancies including hepatocellular carcinoma (HCC). Preclinical and clinical …

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …

Background Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as
promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor …

Summary Background Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately
13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a …

Purpose: On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic
adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims …

Importance Isocitrate dehydrogenase 1 (IDH1) variations occur in up to approximately 20%
of patients with intrahepatic cholangiocarcinoma. In the ClarIDHy trial, progression-free …

Background Treatment options are sparse for patients with advanced cholangiocarcinoma
after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements …

Purpose No standard treatment exists for patients with cholangiocarcinoma for whom first-
line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 (FGFR2) …